InSphero secures Series A financing

05.08.2010 00:00, Pascal Vermot

InSphero AG, a supplier of novel 3D cell-based assays for efficacy testing and toxicology, announced it has secured 1.8 million CHF in a Series A financing led by Redalpine Venture Partners.

InSphero AG is a leading supplier of organotypic, biological 3D microtissues for efficacy testing and toxicology of new compounds in drug development. The company’s three-dimensional microtissues closely resemble native tissue (e.g. liver or tumor) in terms of cellular structure and tissue functionality.

InSphero’s unique technology allows its customers, for the first time, to implement organotypic microtissues as a replacement for conventional, artificial monolayer cultures while still maintaining the same instruments, processes and assays. By easily upgrading cell-based assays from 2D to 3D, compound developers in pharmaceutical and cosmetics industries can achieve better and earlier insights into mode-of-action, efficacy and safety of new compounds; thereby saving time and money.

InSphero will invest the capital from Redalpine, business angels and the Zürcher Kantonalbank (ZKB) to better serve its global customers. Dr. Michael Sidler and Peter Niederhauser will represent Redalpine in the Board of Directors. The Company will create a dedicated sales and customer-support team as well as increase its production capacity for InSphero’s unique portfolio of organotypic microtissues.